Inhibiting the system x<sub>C</sub><sup>-</sup>/glutathione axis selectively targets cancers with mutant-p53 accumulation.
Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ. · 2017
Read Inhibiting the system x<sub>C</sub><sup>-</sup>/glutathione axis selectively targets cancers with mutant-p53 accumulation. by Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5379068.txt.
Introduction
David S. Liu and co-authors found a weak point in mutant-p53 cancers in Nature Communications in 2017. The guard gene TP53 is flawed in more than half of all cancers. The flawed protein piles up in the tumor and marks a poor outlook. Drugs that hit such cancers in a set way are sorely needed. The team traced how the piled protein bends the cell's guard against oxygen harm.
Piled mutant p53 muzzles a gene that builds part of a cystine import pump. With less raw stuff in, the cell makes less glutathione, its main shield against harsh oxygen. Pump-blocking drugs then kill such cells by choice, while sparing sound ones. The muzzled gene's level also flags tumors that will answer a mutant-p53 waking drug. Pairing the two drug types killed the tumors far harder than either alone.
Catalog record
| CREATOR | Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation By David S Liu, Cuong P Duong, Sue Haupt, Karen G Montgomery, Colin M House, Walid J Azar, Helen B Pearson, Oliver M Fisher, Matthew Read, Glen R Guerra, Ygal Haupt, Carleen Cullinane Published in: Nature Communications DOI: 10.1038/ncomms14844 ABSTRACT Abstract TP53, a critical tumour suppressor gene, is mutated in over half of all cancers resulting in mutant-p53 protein accumulation and poor patient survival. Therapeutic strategies to target mutant-p53 cancers are urgently needed. We show that accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine/glutamate antiporter, system xC−, through binding to the master antioxidant transcription factor NRF2. This diminishes glutathione synthesis, rendering mutant-p53 tumours susceptible to oxidative damage. System xC− inhibitors specifically exploit this vulnerability to preferentially kill cancer cells with stabilized mutant-p53 protein. Moreover, we demonstrate that SLC7A11 expression is a novel and robust predictive biomarker for APR-246, a first-in-class mutant-p53 reactivator that also binds and depletes glutathione in tumours, triggering lipid peroxidative cell death. Importantly, system xC− antagonism strongly synergizes with APR-246 to induce apoptosis in mutant-p53 tumours. We propose a new paradigm for targeting cancers that accumulate mutant-p53 protein by inhibiting the SLC7A11–glutathione axis. The tumour suppressor gene TP53 is mutated in a large proportion of cancers. The loss of wild-type p53 (wt-p53) activity and acquisition of oncogenic gain-of-function, secondary to aberrant accumulation of mutant-p53 (mut-p53) protein, frequently results in aggressive tumour phenotypes and poor survival1. Therefore, effective therapies to target mut-p53 cancers are urgently needed. APR-246 (PRIMA-1met) is the most clinically advanced mut-p53 targeting agent and has been shown to reactivate wt-p53 apoptotic functions2. This results in potent anti-tumour activity in preclinical models where drug sensitivity is strongly associated with levels of accumulated mut-p53 protein3. Recently, studies have shown that APR-246 can exert additional effects, particularly through antagonizing the glutathione (GSH) and thioredoxin reductase system4,5, leading to increased reactive oxygen species (ROS). This fuels early speculation that there is potential cross-talk between mut-p53 and redox regulation6. Mounting evidence indicates that cancer cells produce higher levels of ROS compared to normal cells, which in turn can activate mitogenic signalling and promote carcinogenesis7. However, ROS can be a double-edged sword, as excessive accumulation leads to oxidative damage and cell death. These findings have led to the hypothesis that cancer cells with elevated ROS are sensitive to further oxidative insults and therefore can be selectively targeted. Despite compelling preclinical data, human trials of prooxidants have been disappointing7. Thus, it is critical to further elucidate the key modulators of redox balance to design strategies that maximally exploit the redox differential between normal and cancer cells. In this study, we explore in detail the mechanisms and consequences of APR-246-induced oxidative stress. This led us to uncover a crucial link between mut-p53 and cellular redox modulation. We demonstrate that high levels of mut-p53, through binding to NRF2 and impairing its canonical antioxidant activities, directly promote ROS accumulation in cancer cells. This creates an inherent predisposition to further oxidative stress that can be therapeutically harnessed. APR-246 and inhibitors of the cystine/glutamate antiporter, system xC−, take advantage of this vulnerability to selectively kill mut-p53 cancer cells. In combination, these agents synergistically deplete mut-p53 cancers of GSH, leading to overwhelming ROS accumulation and extensive cell death. Importantly, we show that endogenous expression of SLC7A11, a key component of system xC−, reliably predicts tumour response to these therapies. Collectively, we propose a novel strategy to target cancers that accumulate mut-p53, based on perturbation of the SLC7A11–GSH axis. RESULTS APR-246 triggers lipid peroxidation through depleting GSH Using oesophageal cancer as a model, we characterized the mechanisms and consequences of ROS induction by APR-246. Firstly, we verified across a panel of normal and cancer cell lines with differing p53 status (Supplementary Table 1) that treatment with a lethal dose of APR-246 resulted in higher intracellular ROS (Fig. 1a). Extending this, we confirmed that APR-246 rapidly decreases intracellular GSH in mut-p53 cells (Fig. 1b) leading to a concomitant increase in ROS levels, prior to the onset of apoptosis (Supplementary Fig. 1a,b). Furthermore, the pan-caspase inhibitor Q-VD prevented APR-246-induced apoptosis without inhibiting ROS elevation (Supplementary Fig. 1c,d). Altogether, these results suggest that ROS elevation precedes the activation of apoptotic pathways, and is not merely a consequence of cell death. Importantly, APR-246-induced ROS and apoptosis could be prevented by co-culturing with the antioxidants, N-acetyl-cysteine and GSH-monoethyl ester (Fig. 1c,d; Supplementary Fig. 1e,f), highlighting ROS and the GSH pathway as key players in the anti-tumour activity of APR-246. [Figure: Glutathione depletion and ROS induction is central to the anti-tumour activity of APR-246.(a) ROS detected using CellROX 6 h post 50 μM APR-246 treatment across a panel of oesophageal cell lines. Mean fluorescence unit (MFU)±s.e.m. From here on FLO-1 and JH-EsoAd1 cells were treated with their GI90 doses: 25 and 40 μM of APR-246, respectively. (b) Glutathione (GSH) concentrations post APR-246 treatment in FLO-1 and JH-EsoAd1 cells. (c,d) CellROX (c) and viability (d) analysis post treatment with APR-246 and/or 5 mM glutathione-monoethyl ester (GSH-MEE) and/or N-acetyl-cysteine (NAC) in FLO-1 and JH-EsoAd1 cells assayed at 10 and 96 h, respectively. (e) Structural formula of GS-MQ (left) following reaction of MQ with GSH. Typical mass spectrometry (MS) pattern of 100 μM GS-MQ (m/z=445.17 [m+H]) in 0.1% formic acid (right). (f) MS analysis of JH-EsoAd1 cell lysates collected 10 h post vehicle and APR-246 treatment. (g) Absorbance of 10 μM GSH or GS-MQ as measured with the Cayman GSH kit containing GSH reductase. Paired t-test (a), unpaired t-test (b,g), one-way ANOVA with Dunnett's multiple comparison post-test (c,d). Error bars=s.e.m., n=3 for all, *P<0.05, **P<0.01, ***P<0.001. See also Supplementary Fig. 1.] To determine how APR-246 depletes GSH, we applied mass spectrometry to show that 2-methylenequinuclidin-3-one (MQ), the active component of APR-246, reacts with GSH inside cancer cells (Fig. 1e,f). The resultant adduct (GS-MQ) has significantly reduced capacity to participate in GSH recycling via GSH reductase (Fig. 1g), a crucial step in maintaining GSH homoeostasis. Given that intracellular GSH can detoxify xenobiotics through formation of GSH-drug conjugates8, we compared residual GSH levels following APR-246 and chemotherapy treatments. At equi-efficacious doses, APR-246 depleted GSH to a greater extent than cisplatin, 5-fluorouracil, epirubicin, irinotecan and paclitaxel (Supplementary Fig. 1g), further emphasizing the importance of this phenomenon to the activity of APR-246. We next investigated the consequences of APR-246-induced GSH depletion, and found that ROS accumulates in the mitochondria (Fig. 2a), a major reservoir for GSH, leading to lipid peroxidation (Fig. 2b; Supplementary Fig. 2a), mitochondrial rupture (Fig. 2c) and release of the apoptotic initiator, cytochrome c (Fig. 2d). Furthermore, using transmission electron microscopy, we observed a characteristic set of changes in the mitochondria after APR-246 treatment, beginning with organelle condensation and disrupted cristae architecture, followed by gross swelling, loss of outer membrane integrity and eventual rupture (Supplementary Fig. 2b). Importantly, the cytotoxic effects of APR-246 could be rescued with trolox, ferrostatin-1 and 2-mercaptoethanol (Fig. 2e), antioxidants that retard lipid peroxidation9. Incidentally, these are all potent inhibitors of ferroptosis, an iron-dependent, caspase independent form of cell death9. However, the iron-chelator deferoxamine (DFO) did not affect APR-246 activity (Supplementary Fig. 2c), suggesting that GSH depletion by APR-246 triggers lipid peroxidative, but not ferroptotic cell death. [Figure: APR-246